Skip to main content
SpringerLink
Log in

Biological Approaches to the Therapy of Lymphoproliferative Diseases

  • Chapter
Lymphoproliferative Diseases: Pathogenesis, Diagnosis, Therapy

Part of the book series: Developments in Oncology ((DION,volume 31))

  • 30 Accesses

Abstract

Progress has been made over the past 5 years toward the development of specific biological approaches to the treatment of cancer. The techniques of genetic engineering and mass cell culture and improved techniques in protein and nucleic acid sequencing have made available biologics as highly purified molecules. The most definitive investigations have been carried out with the various interferon (IFN) preparations, and it is clear that they are capable of inducing responses primarily in patients with certain types of lymphomas and leukemias. Recent monoclonal antibody data, while interesting, have not yet demonstrated that monoclonal antibodies are effective in the treatment of lymphoma/leukemia. Intensive investigations are currently under way in both of these areas of clinical research.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Merigan TC, Sikora K, Breeden JH, Levy R, Rosenberg JA. 1978. Preliminary observations on the effect of human leukocyte interferon on non-Hodgkin’s lymphoma. N Engl J Med 299:1449–1453.

    Article  PubMed  CAS  Google Scholar 

  2. Louie AC, Gallagher JG, Sikora K, Levy R, Rosenberg SA, Merigan TC. 1981. Follow-up observations on the effect of human leukocyte interferon on non-Hodgkin’s lymphoma. Blood 58:712–718.

    PubMed  CAS  Google Scholar 

  3. Gutterman J, Blumenschein G, Alexanian R, et al. 1980. Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma. Ann Intern Med 93:399–406.

    PubMed  CAS  Google Scholar 

  4. Sherwin SA, Knost JA, Fein S, et al. 1982. A multiple dose phase I trial of recombinant leukocyte A interferon in cancer patients. JAMA 248:2461–2466.

    Article  PubMed  CAS  Google Scholar 

  5. Quesada JR, Reuben J, Manning JR, Hersh EM, Gutterman JU. 1984. Alpha interferon for induction of remission in hairy-cell leukemia. N Engl J Med 310:15–18.

    Article  PubMed  CAS  Google Scholar 

  6. Foon KA, Sherwin SA, Abrams PG, et al. Recombinant leukocyte A interferon: An effective agent for the treatment of advanced non-Hodgkin1s lymphoma. N Engl J Med, in press.

    Google Scholar 

  7. Foon KA, Bottino GC, Abrams PG, et al. Recombinant leukocyte A interferon is not an effective agent for the treatment of advanced chronic lymphocytic leukemia. Am J Med, in press.

    Google Scholar 

  8. Bunn PA, Foon KA, Ihde DC, et al. 1984. Recombinant leukocyte A interferon: An active agent in advanced cutaneous T cell lymphoma. Ann Intern Med 101:484–487.

    PubMed  Google Scholar 

  9. The non-Hodgkin’s lymphoma pathologic classification project. National Cancer Institute sponsored study of classification of non-Hodgkin’s lymphoma. Summary and description of a working formulation for clinical usage. Cancer 49:2112–35, 1982.

    Article  Google Scholar 

  10. Oldham RK. 1983. Monoclonal antibodies in cancer therapy. J Clin Oncol 1(9):582–590.

    PubMed  CAS  Google Scholar 

  11. Levy R, Miller RA. 1983. Tumor therapy with monoclonal antibodies. Fed Proc 42:2650–2756.

    PubMed  CAS  Google Scholar 

  12. Ritz J, Schlossman SF. 1982. Utilization of monoclonal antibodies in treatment of leukemia and lymphoma. Blood 59:1–11.

    PubMed  CAS  Google Scholar 

  13. Ritz J, Pesando JM, Sallan SE, Clavell LA, Notis-McConarty J, Rosenthal P, Schlossman SF. 1981. Serotherapy of acute lymphoblastic leukemia with monoclonal antibody. Blood 58:141–152.

    PubMed  CAS  Google Scholar 

  14. Nadler LM, Stashenko P, Hardy R, et al. 1980. Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res 40:3147–3154.

    PubMed  CAS  Google Scholar 

  15. Dillman RO, Shawler DL, Sobel RE, et al. 1982. Murine monoclonal antibody therapy in two patients with chronic lymphocytic leukemia. Blood 59:1036–1045.

    PubMed  CAS  Google Scholar 

  16. Dillman RO, Shawler DL, Dillman JB, Royston I. 1984. Therapy of chronic lymphocytic leukemia and cutaneous T-cell lymphoma with T101 monoclonal antibody. J Clin Oncol 2:881–891.

    PubMed  CAS  Google Scholar 

  17. Foon KA, Schroff RW, Bunn PA, et al. 1984. Effects of monoclonal antibody therapy in patients with chronic lymphocytic leukemia. Blood, in press.

    Google Scholar 

  18. Miller RA, Maloney DG, McKillop J, Levy R. 1981. In vivo effects of murine hybridoma monoclonal antibody in a patient with T-cell leukemia. Blood 58:78–86.

    PubMed  CAS  Google Scholar 

  19. Miller RA, Levy R. 1981. Response of cutaneous T cell lymphoma to therapy of hybridoma monoclonal antibody. Lancet 2:225–230.

    Google Scholar 

  20. Miller RA, Oseroff AR, Stratte PT, Levy R. 1983. Monoclonal antibody therapeutic trials in seven patients with T-cell lymphoma. Blood 62:988–995.

    PubMed  CAS  Google Scholar 

  21. Foon KA, Schroff RW, Sherwin SA, Oldham RK, Bunn PA, Hsu S-M. 1983. Monoclonal antibody therapy of chronic lymphocytic leukemia and T cell lymphoma: Preliminary observations. In: Monoclonal Antibodies and Cancer. BD Boss, RE Langman, IS Towbridge, R Dulbecco, eds. Academic Press, New York, pp. 39–52.

    Google Scholar 

  22. Hatzubai A, Maloney DG, Levy R. 1981. Use of a monoclonal anti-idiotype antibody to study the biology of a human B cell lymphoma. J Immunol 126:2397–2402.

    PubMed  CAS  Google Scholar 

  23. Miller RA, Maloney DG, Warnke R, Levy R. 1982. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med 306:517–522.

    Article  PubMed  CAS  Google Scholar 

  24. Lowder JN, Meeker TC, Maloney DG, Thielmans K, Miller RA, Levy R. 1984. Anti-idiotype monoclonal antibody therapy of human B lymphocytic malignancy. Proc Am Soc Clin Oncol 3:250.

    Google Scholar 

  25. Sklar J, Cleary ML, Thielemans K, Gralow J, Warnke R, Levy R. 1984. Biclonal B-cell lymphoma. N Engl J Med 311:20–27.

    Article  PubMed  CAS  Google Scholar 

  26. Raffeld M, Cossman J. 1984. Instability of idiotype in follicular lymphomas. Blood (Suppl. 1).

    Google Scholar 

  27. Oldham RK, Foon KA, Morgan AC, et al. 1984. Monoclonal antibody therapy of malignant melanoma: In vivo localization in cutaneous metastasis after intravenous administration. J Clin Oncol, in press.

    Google Scholar 

  28. Schroff RW, Farrell MM, Klein RA, Giardina SL, Oldham RK, Foon KA. 1984. T65 antigen modulation in a chronic lymphocytic leukemia phase I monoclonal antibody trial. J Immunol 133:1641–1648.

    PubMed  CAS  Google Scholar 

  29. Schroff RW, Foon KA, Wilburn SB, Oldham RK, Morgan AC. 1984. Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy. Cancer Res, in press.

    Google Scholar 

  30. Sears HF, Herlyn D, Steplewski Z, Koprowski H. 1984. Effects of monoclonal antibody immunotherapy on patients with gastrointestinal adenocarcinoma. J Biol Resp Modif 3:138–150.

    CAS  Google Scholar 

  31. Foon KA, Bernhard MI, Oldham RK. 1982. Monoclonal antibody therapy: Assessment by animal tumor models. J Biol Resp Modif 1:277–304.

    Google Scholar 

  32. Goldenberg DM, DeLand FH. 1982. History and status of tumor imaging with radiolabeled antibodies. J Biol Resp Modif 1:121–136.

    Google Scholar 

  33. Goldenberg DM, DeLand FH, Kim EE, et al. 1978. Use of radiolabeled antibody to carcinoembryonic antigen for the detection and localization of diverse cancers by external photoscanning. N Engl J Med 298:1384–1388.

    Article  PubMed  CAS  Google Scholar 

  34. Mach J-P, Carrel S, Forni M, Ritschard J, Donath A, Alberto P. 1980. Tumor localization of radiolabeled antibodies against carcino-embryonic antigen in patients with carcinoma. N Engl J Med 303:5–10.

    Article  PubMed  CAS  Google Scholar 

  35. Larsen SM, Carresguillo JA, Krohn KA, et al. 1982. Localization of 131I-labeled p97-specific Fab fragments in human melanoma as a basis for radiotherapy. J Clin Invest 72:2101–2114.

    Article  Google Scholar 

  36. Mach J-P, Buchegger F, Forni M, et al. 1981. Use of radiolabeled monoclonal anti-CEA antibodies for detection of human carcinomas by external photoscanning and tomoscintigraphy. Immunol Today, December: 239–249.

    Google Scholar 

  37. Epenetos AA, Britton KE, Mather S, et al. 1982. Targeting of mature 123-labeled tumour associated monoclonal antibodies to ovarian, breast, and gastrointestinal tumors. Lancet 2:999–1004.

    Article  PubMed  CAS  Google Scholar 

  38. Smedley HM, Finan P, Lennox ES, et al. 1983. Localization of metastatic carcinoma by a radiolabeled monoclonal antibody. Br J Cancer 47:253–259.

    Article  PubMed  CAS  Google Scholar 

  39. Fanands PA, Perkins AC, Pimm MV, et al. 1982. Radio-immunodetection of human colorectal cancers by an anti-tumour monoclonal antibody. Lancet 2:397–400.

    Article  Google Scholar 

  40. Order SE, Klein JL, Leichner PK, Wharham MD, Ettinger DS, Siegelman SS. 1982. Advances in iodine 131-labeled antiferritin immunoglobulin cancer therapy. Cancer Bulletin 34: 264–267.

    Google Scholar 

  41. Ritz J, Bast RC, Clavell LA, et al. 1982. Autologous bone marrow transplantation in CALLA-positive acute lymphoblastic leukemia after in vitro treatment with J5 monoclonal antibody and complement. Lancet 2:60–63.

    Article  PubMed  CAS  Google Scholar 

  42. Nadler L, Takvorian T, Botnick L, et al. 1984. Anti-Bl monoclonal antibody and complement treatment in autologous bone-marrow transplantation for relapsed B-cell non-Hodgkin’s lymphoma. Lancet 2:427–431.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Kenneth A. Foon
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Hemathopathology Section, Department of Pathology, U.S.C. School of Medicine, Los Angeles, California, USA

    Paul K. Pattengale M.D. , Robert J. Lukes M.D.  & Clive R. Taylor M.B., B.Chir., D.Phil. ,  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1985 Martinus Nijhoff Publishers, Dordrecht

About this chapter

Cite this chapter

Foon, K.A. (1985). Biological Approaches to the Therapy of Lymphoproliferative Diseases. In: Pattengale, P.K., Lukes, R.J., Taylor, C.R. (eds) Lymphoproliferative Diseases: Pathogenesis, Diagnosis, Therapy. Developments in Oncology, vol 31. Springer, Dordrecht. https://doi.org/10.1007/978-94-009-5016-0_13

Download citation

  • DOI: https://doi.org/10.1007/978-94-009-5016-0_13

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-010-8721-6

  • Online ISBN: 978-94-009-5016-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation